Everything below concerns DAC group. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-28. Numbers and descriptions here follow the published literature rather than marketing material.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Valve announced Steam, its digital distribution service, at the 2002 Game Developers Conference. It was launched in September 2003 and was first used to deliver patches and other updates to Valve's online games. On August 1, 2012, Valve announced revisions to the Steam Subscriber Agreement (SSA) to prohibit class action lawsuits by users against the service provider. By July 2014, there were over 3,400 games available on Steam, with over 150 million registered accounts by January 2018. Alongside these changes to the SSA, the company also declared publicly the incorporation of Valve S.a.r.l., a subsidiary based in Luxembourg. Valve set up a physical office in Kirchberg, Luxembourg. According to Valve's project manager Mike Dunkle, the location was chosen for eCommerce capabilities and infrastructure, talent acquisition, tax advantages and central geographic location – most major partners are accessible, 50% within driving distance. Valve S.a.r.l. was used to sell games to UK users to avoid paying the full 20% value-added tax (VAT). The tax loophole was expected to close on January 1, 2015. In December 2015, the French consumer group UFC Que Choisir initiated a lawsuit against Valve for several of its Steam policies that conflict or run afoul of French law. One of the reasons was for using the tax loophole. Valve S.a.r.l. ceased business on January 1, 2017, with the main company taking over EU sales again. In August 2017, Valve announced that Steam had reached over 67 million monthly and 33 million daily active users on the platform.
The spleen is the largest lymphoid organ in the body but has other functions. It breaks down both red and white blood cells that are spent. This is why it is sometimes known as the 'graveyard of red blood cells'. A product of this digestion is the pigment bilirubin, which is sent to the liver and secreted in the bile. Another product is iron, which is used in the formation of new blood cells in the bone marrow. Medicine treats the spleen solely as belonging to the lymphatic system, though it is acknowledged that the full range of its important functions is not yet understood.
Hahn remained modest and informal all his life. His disarming frankness, unfailing kindness, good common sense, and impish humour will be remembered by his many friends all over the world. The Royal Society in London wrote in an obituary:
Sources: en.wikipedia.org
=== Filming === Scouting began in the beginning of July. The table read for the first episode was announced to occur on July 14, 2015, by Kerry Washington. The title of the season premiere, "Heavy is the Head" was revealed on August 8, 2015, by its director Tom Verica on Twitter. Filming for the season began on July 16, 2015. Several actors working on ShondaLand-produced shows directed an episode for the fifth season. Tony Goldwyn from Scandal directed the second and 17th episodes, making it the fourth and fifth episodes he has directed on the show. Chandra Wilson, who plays Dr. Miranda Bailey on Grey's Anatomy, directed her first Scandal episode, which was the sixth episode "Get Out of Jail, Free". Scott Foley from Scandal also directed his first Scandal episode, the 16th named "The Miseducation of Susan Ross". Foley's director-debut was announced on Twitter by Foley himself and executive producer Tom Verica.
Kennedy decided toward the end of 1871 to end his business partnership with Eddy. She had accused him in front of others of cheating at cards; it was one of several scenes she had caused between them and he walked out on her. There was a temporary reconciliation, but he was unhappy about the abandonment of head rubbing, and after a dispute between Eddy and a student over a refund was played out in the local press, he decided to go his own way. Once Kennedy and Eddy had settled their financial affairs in May 1872, she was left with $6,000. Peel writes that at this point she had already written 60 pages of Science and Health. She was renting rooms in Lynn at 9 Broad Street, when 8 Broad Street came on the market. In March 1875 she purchased it for $5,650, taking in students to pay the mortgage. It was in the attic room of this house that she completed Science and Health. Shortly after moving in, Eddy became close to another student, Daniel Spofford. He was 33 years old and married when he joined her class; he later left his wife in the hope that he might marry Eddy, but his feelings were not reciprocated. Spofford and seven other students agreed to form an association that would pay Eddy a certain amount a week if she would preach to them every Sunday. They called themselves the Christian Scientists' Association. Eddy placed a sign on 8 Broad Street: "Mary B.
=== David Healy === David Maurice Healy is played by Johnny Galecki. David is Mark Healy's younger brother. He first appeared in "The Bowling Show" (episode 4.14). Whereas Mark was initially a rebellious delinquent, David is friendly and respectful to the Conners. He is shy, polite, thoughtful, sensitive, soft-spoken, artistic, and intelligent. Much of his passive behavior results from his difficult home life and his mother's abusive behavior. He is romantically involved with Darlene, becoming the submissive partner. They also collaborate artistically, with David illustrating graphic novels that Darlene writes. His sweet manner endears him to the Conners, who eventually consider him as part of the family and jokingly refer to him as being more welcome than Darlene. He moves in with the Conners after Roseanne, herself a victim of child abuse, witnesses how abusive David's mother is. David and Darlene break up three times throughout the series, each for a successively longer period of time, but always reunite. After Darlene becomes pregnant, she and David married. In the series finale, Roseanne reveals in her writing that David had actually been dating Becky in "real life", and that Roseanne simply wrote his relationship as being with Darlene because she felt it made more sense. The series finale is retconned for season 10, where it is revealed that David and Darlene have been separated for some years and David has been away, traveling and doing volunteer work abroad, leaving Darlene to raise their two children, Harris and Mark, as a single mother.
== Bibliography (in French) == Deligeorges, Stephane; Gady, Alexandre; Labalette, Françoise (2004). Le Jardin des Plantes et le Muséum national d'histoire naturelle (in French). Éditions du Patrimoine- Centre des Monuments Nationaux. ISBN 978-2-85822-601-6.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.